Biogen (BIIB) Construction in Progress (2009 - 2025)
Biogen (BIIB) posted quarterly Construction in Progress of $163.1 million for Q4 2025, down 47.11% year-over-year from $308.4 million in Q4 2024, and down 47.11% quarter-over-quarter from $308.4 million in Q4 2024.
Biogen (BIIB) Construction in Progress (2009 - 2025) Analysis & Trends
Biogen's Construction in Progress history runs 17 years deep, the most recent figure standing at $163.1 million for Q4 2025.
- In Q4 2025, Construction in Progress fell 47.11% year-over-year to $163.1 million; the TTM figure through Dec 2025 stood at $163.1 million (down 47.11% YoY), while the FY2025 annual figure was $163.1 million, down 47.11% from the prior year.
- Construction in Progress for Q4 2025 stood at $163.1 million, down from $308.4 million in the prior quarter.
- The five-year high for Construction in Progress was $1.9 billion in Q1 2021, with the low at $163.1 million in Q4 2025.
- The 5-year median for Construction in Progress is $711.1 million (2022), against an average of $754.1 million.
- The sharpest annual moves came in 2022 and 2024: Construction in Progress advanced 15.38% in 2022, then slumped 68.38% in 2024.
- Biogen's Construction in Progress stood at $770.3 million in 2021, then increased by 15.38% to $888.8 million in 2022, then advanced by 9.74% to $975.4 million in 2023, then sank by 68.38% to $308.4 million in 2024, then plunged by 47.11% to $163.1 million in 2025.
- Business Quant data shows BIIB's Construction in Progress at $163.1 million in Q4 2025, $308.4 million in Q4 2024, and $975.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 163.10 Mn |
| Dec 31, 2024 | 308.40 Mn |
| Dec 31, 2023 | 975.40 Mn |
| Sep 30, 2023 | 742.00 Mn |
| Jun 30, 2023 | 732.20 Mn |
| Mar 31, 2023 | 721.20 Mn |
| Dec 31, 2022 | 888.80 Mn |
| Sep 30, 2022 | 701.00 Mn |
| Jun 30, 2022 | 691.70 Mn |
| Mar 31, 2022 | 682.60 Mn |
| Dec 31, 2021 | 770.30 Mn |
| Sep 30, 2021 | 661.80 Mn |
| Jun 30, 2021 | 618.40 Mn |
| Mar 31, 2021 | 1.90 Bn |
| Dec 31, 2020 | 1.95 Bn |
| Sep 30, 2020 | 1.80 Bn |
| Jun 30, 2020 | 1.70 Bn |
| Mar 31, 2020 | 1.70 Bn |
| Dec 31, 2019 | 2.08 Bn |
| Sep 30, 2019 | 1.80 Bn |